Valeo Financial Advisors LLC Boosts Stock Holdings in Stryker Corporation $SYK

Valeo Financial Advisors LLC raised its stake in Stryker Corporation (NYSE:SYK) by 22.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 9,572 shares of the medical technology company’s stock after buying an additional 1,769 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Stryker were worth $3,787,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of SYK. Consolidated Portfolio Review Corp grew its position in Stryker by 4.2% during the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock worth $256,000 after purchasing an additional 26 shares during the last quarter. Princeton Global Asset Management LLC lifted its stake in shares of Stryker by 16.9% during the second quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after buying an additional 26 shares during the period. Sunflower Bank N.A. grew its holdings in shares of Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after buying an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC increased its position in shares of Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after acquiring an additional 27 shares during the period. Finally, Sachetta LLC raised its stake in Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Performance

SYK opened at $353.99 on Monday. The firm has a fifty day moving average price of $366.81 and a 200 day moving average price of $378.45. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The stock has a market cap of $135.37 billion, a P/E ratio of 46.52, a P/E/G ratio of 2.51 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. During the same quarter in the previous year, the company earned $2.87 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Wednesday, December 31st will be given a dividend of $0.88 per share. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, December 31st. Stryker’s dividend payout ratio (DPR) is currently 44.15%.

Insider Buying and Selling at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Preston Wendell Wells sold 165 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the transaction, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This trade represents a 2.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 522,118 shares of company stock valued at $185,381,932. Company insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on SYK shares. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Barclays increased their price target on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Redburn Partners set a $420.00 price objective on shares of Stryker in a research note on Thursday, September 18th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 price objective on shares of Stryker in a research note on Friday, November 14th. Finally, Citigroup lowered their price target on shares of Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $431.83.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.